Changchun High-Tech Industry (000661.SZ)'s subsidiary's clinical trial application for GenSci161 Injection has been accepted.

date
20:02 20/11/2026
avatar
GMT Eight
Changchun High-Tech Industry (000661.SZ) announced that recently, its controlling subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharmaceutical") received the Notice of Acceptance issued upon approval by the National Medical Products Administration, and the domestic production drug registration clinical trial application for Jinsai Pharmaceutical's GenSci161 Injection has been accepted. GenSci161 Injection is a Class 1 new therapeutic biologic independently developed by Jinsai Pharmaceutical. It is a novel fully human monoclonal IgG1 bispecific antibody, intended for the treatment of pyoderma gangrenosum (PG) and cryopyrin-associated periodic syndrome (CAPS).
Changchun High-Tech Industry (000661.SZ) announced that recently, its controlling subsidiary Changchun GeneScience Pharmaceutical Co., Ltd. ("GeneScience Pharmaceutical") received the Notice of Acceptance issued upon approval by the National Medical Products Administration, and GeneScience Pharmaceutical's domestic production drug registration clinical trial application for GenSci161 Injection has been accepted. GenSci161 Injection is a Class 1 new therapeutic biologic independently developed by GeneScience Pharmaceutical. It is a novel fully human monoclonal IgG1 bispecific antibody, intended for the treatment of pyoderma gangrenosum (PG) and cryopyrin-associated periodic syndrome (CAPS).